abs342.txt	purpose	the	aim	of	the	current	study	was	to	characterize	the	risk	of	intervalinvasive	second	breast	cancers	within	5	years	of	primary	breast	cancer	treatment	methods	we	examined	65	084	surveillance	mammograms	from	18	366	women	with	aprimary	breast	cancer	diagnosis	of	unilateral	ductal	carcinoma	in	situ	or	stage	ito	iii	invasive	breast	carcinoma	performed	from	1996	to	2012	in	the	breast	cancersurveillance	consortium		interval	invasive	breast	cancer	was	defined	asipsilateral	or	contralateral	cancer	diagnosed	within	1	year	after	a	negativesurveillance	mammogram		discrete-time	survival	models-adjusted	for	allcovariates-were	used	to	estimate	the	probability	of	interval	invasive	cancer	given	the	risk	factors	for	each	surveillance	round		and	aggregated	across	roundsto	estimate	the	5-year	cumulative	probability	of	interval	invasive	cancer	results	we	observed	474	surveillance-detected	cancers-334	invasive	and	140	ductalcarcinoma	in	situ-and	186	interval	invasive	cancers	which	yielded	a	cancerdetection	rate	of	7	3	per	1	000	examinations	(95%	ci		6	6	to	8	0)	and	an	intervalinvasive	cancer	rate	of	2	9	per	1	000	examinations	(95%	ci		2	5	to	3	3)		mediancumulative	5-year	interval	cancer	risk	was	1	4%	(interquartile	range		0	8%	to2	3%		10th	to	90th	percentile	range		0	5%	to	3	7%)		and	15%	of	women	had	â‰¥	3%5-year	interval	invasive	cancer	risk		cumulative	5-year	interval	cancer	risk	washighest	for	women	with	estrogen	receptor-	and	progesterone	receptor-negativeprimary	breast	cancer	(2	6%		95%	ci		1	7%	to	3	5%)		interval	cancer	presentationat	primary	diagnosis	(2	2%		95%	ci		1	5%	to	2	9%)		and	breast	conservationwithout	radiation	(1	8%		95%	ci		1	1%	to	2	4%)		conclusion	risk	of	intervalinvasive	second	breast	cancer	varies	across	women	and	is	influenced	bycharacteristics	that	can	be	measured	at	initial	diagnosis		treatment		andimaging		risk	prediction	models	that	evaluate	the	risk	of	cancers	not	detected	bysurveillance	mammography	should	be	developed	to	inform	discussions	of	tailoredsurveillance	
